

## Assessment of Cardiovascular Risk and Prevention of Cardiovascular Disease in Women with the Polycystic Ovary Syndrome: A Consensus Statement by the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society

Robert A. Wild, Enrico Carmina, Evanthia Diamanti-Kandarakis, Anuja Dokras, Hector F. Escobar-Morreale, Walter Futterweit, Rogerio Lobo, Robert J. Norman, Evelyn Talbott, and Daniel A. Dumesic

Oklahoma University Health Sciences Center (R.A.W.), Oklahoma City, Oklahoma 73104; University of Palermo (E.C.), 90139 Palermo, Italy; University of Athens Medical School (E.D.-K.), 11527 Athens, Greece; University of Pennsylvania (A.D.), Philadelphia, Pennsylvania 19104; Hospital Ramon y Cajal (H.F.E.-M.), 28034 Madrid, Spain; Mount Sinai School of Medicine (W.F.), New York, New York 10029; Columbia University (R.L.), New York, New York 10027; University of Adelaide (R.J.N.), Adelaide SA 5005, Australia; University of Pittsburgh (E.T.), Pittsburgh, Pennsylvania 15261; and University of Wisconsin (D.A.D.), Madison, Wisconsin 53792

**Objective:** Women with polycystic ovary syndrome (PCOS) often have cardiovascular disease (CVD) risk factors. The Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society created a panel to provide evidence-based reviews of studies assessing PCOS-CVD risk relationships and to develop guidelines for preventing CVD.

**Participants:** An expert panel in PCOS and CVD reviewed literature and presented recommendations.

**Evidence:** Only studies comparing PCOS with control patients were included. All electronic databases were searched; reviews included individual studies/databases, systematic reviews, abstracts, and expert data. Articles were excluded if other hyperandrogenic disorders were not excluded, PCOS diagnosis was unclear, controls were not described, or methodology precluded evaluation. Inclusion/exclusion criteria were confirmed by at least two reviewers and arbitrated by a third.

**Consensus Process:** Systematic reviews of CVD risk factors were compiled and submitted for approval to the AE-PCOS Society Board.

**Conclusions:** Women with PCOS with obesity, cigarette smoking, dyslipidemia, hypertension, impaired glucose tolerance, and subclinical vascular disease are at risk, whereas those with metabolic syndrome and/or type 2 diabetes mellitus are at high risk for CVD. Body mass index, waist circumference, serum lipid/glucose, and blood pressure determinations are recommended for all women with PCOS, as is oral glucose tolerance testing in those with obesity, advanced age, personal history of gestational diabetes, or family history of type 2 diabetes mellitus. Mood disorder assessment is suggested in all PCOS patients. Lifestyle management is recommended for primary CVD prevention, targeting low-density and non-high-density lipoprotein cholesterol and adding insulin-sensitizing and other drugs if dyslipidemia or other risk factors persist. (*J Clin Endocrinol Metab* 95: 2038–2049, 2010)

**P**olycystic ovary syndrome (PCOS) is a common endocrinopathy affecting 6–10% of reproductive-aged women (1–3) and manifested by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries in its complete phenotype (4). Although evidence for cardiovascular events in women who were affected by PCOS during fertile age is limited (5), available data suggest more frequent cardiovascular disease (CVD) in classic PCOS (5). In young women with PCOS, multiple risk factors for CVD, including metabolic syndrome (MBS), type 2 diabetes mellitus (T2DM), dyslipidemia, abdominal obesity, and hypertension (5–7) may be found, and prevention of future cardiovascular adverse effects is needed. With increased adiposity in two thirds of American PCOS women (8), the degree to which obesity and PCOS interact to promote premature atherosclerosis and increase cardiovascular mortality is a worldwide concern (9–14).

Therefore, the Androgen Excess and Polycystic Ovary Syndrome (AE-PCOS) Society appointed a panel to review all published evidence assessing CVD risk in PCOS *vs.* non-PCOS women and to recommend PCOS-related guidelines for CVD prevention. An important consideration was the broader definition of PCOS [*i.e.* Rotterdam 2003 (15) or AE-PCOS 2006 (4)] *vs.* the more restrictive NIH 1990 criteria (16). The former non-NIH criteria include more women (17) and increase heterogeneity of PCOS phenotypic expression. The following statement provides consensus recommendations based on systematic reviews for screening and preventing CVD risk factors in PCOS.

## Materials and Methods

### Panel

The AE-PCOS Board appointed a panel of experts in PCOS and CVD. Panel members and Board Directors constituted the Writing Committee. No external funds were used.

### Data

Systematic reviews of published peer-reviewed medical literature identified studies evaluating CVD risk factors for women (18) with and without PCOS. Multiple databases were queried, including MEDLINE, EMBASE, Cochrane, ERIC, EBSCO, dissertation abstracts, and current contents. Reviews evaluated prevalence of obesity, metabolic dysfunction, MBS, depression, inflammation, dyslipidemia, hypertension, physical inactivity, and interventions comparing PCOS *vs.* control women with and without weight matching. Articles were excluded by consensus if other hyperandrogenic disorders were not excluded, PCOS diagnosis was uncertain, controls were not described, or methodology precluded risk factor assessment. More than 1000 articles were initially available for review, with some studies eliminated because data were insufficient for epidemiological analysis or were reported in previous publications. All data sources were analyzed recognizing positive publication bias.

### Process

The committee critiqued each review, considering Endocrine Society guidelines for primary CVD prevention in patients at metabolic risk, before submitting the manuscript to the AE-PCOS Society Board for approval (19). Reviews included individual studies, systematic reviews, hand searches, abstracts, and individual databases and expert data. Each systematic review was conducted by at least three investigators, and criteria for inclusion/exclusion were agreed upon by at least two reviewers in each area and arbitrated by a third when necessary. The position statement applied part of the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) group criteria (20, 21), in which strength of a recommendation was indicated “recommend” or a weaker recommendation was indicated “suggest.” Recommendations were accompanied by evidence that was considered in making the recommendation. Institutional Review Board approval was not obtained because the study reviewed publicly available literature.

## PCOS Phenotype

A crucial factor in assessing CVD risk for a woman with PCOS is the definition of PCOS itself (Table 1). When Rotterdam or AE-PCOS *vs.* “classic” NIH criteria are applied, the prevalence of PCOS in the population increases to over 20% (22), with approximately 75% of referred PCOS patients having classic PCOS and the remaining 25% evenly divided between ovulatory and nonhyperandrogenic PCOS phenotypes (23). Women with classic PCOS have greater menstrual irregularity, hyperandrogenism, total and abdominal obesity, and insulin resistance (IR) and have more severe risk factors for T2DM and CVD than PCOS patients diagnosed using non-NIH criteria (24–29). Ovulatory PCOS patients have lower body mass index (BMI) and abdominal obesity, lesser degrees of hyperandrogenism and hyperinsulinemia, reduced MBS

**TABLE 1.** Diagnostic criteria for PCOS

Criteria	NIH 1990 “classic”	Rotterdam 2003	AE-PCOS
Oligomenorrhea <sup>a</sup>	+	+/-	+/-
Clinical or biochemical hyperandrogenism <sup>b</sup>	+	+/-	+
Polycystic ovaries on ultrasound <sup>c</sup>	+/-	+/-	+/-

NIH, Presence of both oligomenorrhea and clinical/biochemical hyperandrogenism; Rotterdam, any two of the above criteria; AE-PCOS, presence of clinical/biochemical hyperandrogenism and one other criterion.

<sup>a</sup> Eight or less menses per year.

<sup>b</sup> Acne or hirsutism or androgenic alopecia.

<sup>c</sup> Ovarian volume > 10 ml and/or > 12 follicles less than 9 mm in size in at least one ovary.

prevalence, and milder forms of dyslipidemia (24–27, 29), whereas nonhyperandrogenic PCOS patients have the most metabolically favorable profile, often indistinguishable from normal women (25, 28, 30, 31).

## CVD Risk Factors

Most CVD risk factor studies have been conducted in women with classic PCOS (NIH criteria), often before new criteria were developed, with several studies comparing PCOS and control women using BMI matching (14, 32–35). Differences between PCOS and control women exist in several CVD risk factors, which often are more profound in obese PCOS women (33, 35).

### Impaired glucose tolerance (IGT)

IR occurs in approximately 60–80% of women with PCOS and in 95% of obese women with PCOS (36, 37). In most classic cases of PCOS, insulin-mediated glucose uptake is impaired, but the precise mechanism remains elusive (38, 39). These women with PCOS have IR independent and additive with that of obesity, with PCOS and obesity acting synergistically to impair insulin sensitivity (38).

Consequently, IGT and MBS, as predictors of T2DM and premature CVD mortality (40–42), are prevalent in women with PCOS (odds ratio, approximately 4:1) (43, 44). Alarming, IGT and T2DM are highly prevalent among PCOS adolescents (45), and, although incident data are not rigorous, up to 40% of women with classic PCOS develop IGT or T2DM by the fourth decade of life (46, 47), with age and weight gain worsening glycemic control (46–48). In one study, classic PCOS patients had a 5-fold risk of developing T2DM over 8 yr *vs.* age- and weight-matched controls (48), although only 12% of PCOS patients without obesity developed glucose abnormalities (47).

### Dyslipidemia

Dyslipidemia is very common in PCOS patients (up to 70% in the United States) (33, 49) and may present with different patterns, including low levels of high-density lipoprotein (HDL)-cholesterol (HDL-C), increased values of triglycerides and total and low-density lipoprotein (LDL)-cholesterol (LDL-C), as well as altered LDL quality (7, 33, 49–52). These different patterns may be related to the associated effects of IR and hyperandrogenism that combine with environmental (diet, physical exercise) and genetic factors (51, 52).

The most common pattern is probably the so-called atherogenic lipoprotein phenotype that is characterized by hypertriglyceridemia, increased small dense LDL-C levels, and decreased HDL-C levels (53, 54). This lipid pattern is

similar to that found in T2DM (55), and it is mainly the consequence of IR that impairs the ability of insulin to suppress lipolysis, thereby increasing mobilization of free fatty acids from adipose stores. Consequently, increased hepatic delivery of free fatty acids impairs insulin inhibition of hepatic very low-density lipoprotein 1 synthesis, causing altered catabolism of very low-density lipoprotein (55). Because excessive adipose tissue increases IR (56), this pattern is more common in obese patients with PCOS. It occurs in the United States in about 70% of women with classic PCOS (51, 57) but is less common in other countries where mean body weight is lower (51). However, also in Mediterranean countries, about one half of women with PCOS have low HDL-C and a small dense LDL phenotype (50, 51, 58). Therefore, it is not surprising that current diagnostic guidelines recommend measuring serum triglycerides and HDL-C, although only in obese PCOS women (15).

Many studies have shown that LDL-C also is increased in women with PCOS (6, 33, 51, 52). The prevalence of increased LDL-C in PCOS is generally lower than that found for the atherogenic dyslipidemia and ranges from 24 to 40% (51, 52), but it is less dependent on body weight and may be partially related to the hyperandrogenism (52, 59).

The available evidence shows that different lipid patterns may be present in women with PCOS. In addition, differences between diverse ethnic and geographical backgrounds cannot be fully explained by variations in body weight alone (51, 52) but are likely to depend on the combination of genetic, environmental, and hormonal factors. In support of this, nonobese women with PCOS also can have elevated levels of lipoprotein (a) (29), a stable, genetically and racially determined, lipid-rich, LDL-like lipoprotein that is metabolically distinct from LDL-C (60).

### MBS

Linked with IR is MBS, defined as elevated blood pressure (BP) ( $\geq 130/85$  mm Hg), increased waist circumference ( $\geq 88$  cm, non-Asian;  $\geq 80$  cm, East/South Asian women), elevated fasting glucose ( $\geq 100$  mg/dl), reduced HDL-C ( $\leq 50$  mg/dl in women), and elevated triglyceride ( $\geq 150$  mg/dl) levels (19). Central to MBS is abdominal adiposity, which in PCOS is increased *vs.* controls, even in some (27, 61, 62) but not all (63, 64) nonobese individuals. Abdominal adiposity in PCOS worsens with weight gain to increase the risk of cardiovascular death, after adjusting for BMI (64, 65). The estimated prevalence of MBS in classic PCOS in the United States is 33–47% (12, 33, 43, 66, 67), about two to three times higher than that of age-matched controls (34, 66–68) and 13.7 times more likely in women with PCOS in the highest *vs.* the lowest BMI

quartile (66). In other countries, the prevalence of MBS is lower, ranging between 8 and 25% in women with classic PCOS (69, 70). Although the prevalence of MBS is high in PCOS, adjusting for BMI, it is lower if there is not excessive abdominal adiposity (66, 71).

Accompanying MBS in PCOS is an inflammatory atherothrombotic IR that elevates several proinflammatory substances (C-reactive protein, fibrinogen, white blood cells, plasminogen activator inhibitor-1, and endothelin-1), which impair endothelial function, reduce vasoreactivity, and promote subclinical atherosclerosis (72, 73).

### Depression, anxiety, and reduced quality of life

There is growing evidence that mood disturbances, mostly severe depression, are independent CVD risk factors (18) and prevalent in women with PCOS (74, 75). Several studies show increased depression and anxiety in PCOS patients (74–77), in whom impaired quality of life from body image concerns cause fatigue, sleep disturbances, phobia, appetite changes, and binge eating (75–77). As a result, depressed women with PCOS have higher BMI and greater IR as CVD risk factors than nondepressed women with PCOS without differences in androgen excess (76), whereas weight loss through an energy-restricted diet improves their depression and quality of life (78). It remains to be determined how mood disturbances as CVD risk factors are linked with altered stress reactivity in women with PCOS, as evidenced by exaggerated ACTH and cortisol stress responses (79), impaired IL-6 up-regulation after stress (79), and heightened sympathetic nerve activity (80).

## CVD Outcomes

### Markers of atherosclerosis

Women with PCOS have more subclinical vascular disease *vs.* controls, adjusting for age and BMI. Wild *et al.* (81) found that increased waist/hip ratio and hirsutism were associated with confirmed coronary artery disease in women age 60 yr or older undergoing coronary angiography. Birdsall *et al.* (9) evaluated 143 women younger than 60 yr undergoing coronary angiography for chest pain or valvular disease and detected polycystic ovaries in 42% of these women, although NIH or Rotterdam criteria were not applied. Women with PCOS had more advanced coronary artery disease than women with normal ovaries.

Guzick *et al.* (10) evaluated 16 hyperandrogenic premenopausal women at least 40 yr of age, diagnosed previously with PCOS, compared with 16 age-matched regularly cycling controls undergoing carotid artery scanning and found mean carotid intima-media thickness (IMT) significantly greater in PCOS patients (0.68 mm) than con-

trols (0.63 mm). Talbott *et al.* (82) evaluated 125 Caucasian women with PCOS and 142 age-matched controls and confirmed greater carotid-IMT in PCOS patients (0.78 mm) than controls 45 yr of age and older (0.70 mm), which remained significant after adjusting for BMI. Other studies have shown increased carotid-IMT in overweight and normal-weight women with PCOS (83, 84).

Two studies have measured coronary artery calcification (CAC), a marker of subclinical coronary atherosclerosis (13, 34). Using NIH criteria and adjusting for age and BMI, both studies suggest that women with PCOS have a greater CAC prevalence than controls, independent of age and BMI, although small sample sizes and the young age of the population precluded analysis of a range of CAC levels.

### Cardiovascular events

Evidence for increased CVD morbidity and mortality is inconclusive, yet suggestive, given challenges with the current epidemiological studies. Of eight studies (11, 12, 14, 32, 85–88), four used Rotterdam and/or NIH criteria for PCOS and followed PCOS cases for CVD endpoints; designs are cross-sectional with small numbers (32, 85) or prospective with larger numbers (11, 12).

Initial studies did not find an increased prevalence of nonfatal/fatal CVD in women with PCOS (11, 12), although risk for nonfatal cerebrovascular disease appeared to be higher (12). However, a recent substudy of the Women's Ischemia Evaluation Study (WISE) (14) confirmed that women with PCOS have a larger number of cardiovascular events. In this study, multivessel CVD was observed in 32% of PCOS women compared with 25% of non-PCOS women (odds ratio, 1.7) and correlated with several factors, including increased free testosterone. In addition, the event free survival (including fatal and nonfatal events) was significantly lower in PCOS compared with non-PCOS women. The difference between the two groups was higher when cerebrovascular accidents were considered too, confirming the association of PCOS with stroke.

Two additional studies give further support to the association between PCOS and CVD. Krentz *et al.* (87) conducted a cross-sectional study of 713 postmenopausal women (mean age, 73.8 yr) and found in nondiabetic women with intact ovaries a stepwise graded association between CVD and numbers of features of putative PCOS, as defined by premenopausal menstrual irregularity, hirsutism, or current biochemical hyperandrogenism. Azevedo *et al.* (88) performed a case-control study of 414 postmenopausal women (mean age, 60.4 yr) and also noted in women with premenopausal menstrual irregularity (as a putative sign of PCOS) an increased odds ratio for coronary vascular disease.



*In toto*, the present epidemiological data suggest more frequent CVD in classic PCOS, mostly mediated through increased total and abdominal adiposity, and perhaps interacting with PCOS-related hyperandrogenism.

## Assessing CVD Risk Factors in PCOS

Because lifetime risk for CVD in all women is high and mostly preventable, all women should be screened for CVD risk factors (89). Evidence-based guidelines for women provided by the American Heart Association (AHA) (89) classify women for CVD risk as: 1) optimal risk; 2) at risk; or 3) at high risk.

Recognizing that PCOS women with increased adiposity are at greater risk for T2DM, stroke, and CVD, the committee *recommends* that PCOS-related CVD risk be categorized as:

1. At risk—PCOS women with any following risk factors:

- Obesity (especially increased abdominal adiposity)
- Cigarette smoking
- Hypertension
- Dyslipidemia (increased LDL-C and/or non-HDL-C)
- Subclinical vascular disease
- IGT
- Family history of premature CVD (<55 yr of age in male relative, <65 yr of age in female relative) (89), or

2. At high risk—PCOS women with:

- MBS
- T2DM
- Overt vascular or renal disease

Because adolescent PCOS women acquire IR (90) as an antecedent to T2DM and CVD, lifetime CVD prevention strategies are of greater value for younger than older women (18). Therefore, all women with PCOS should be assessed for CVD risk. Accordingly, we *recommend* that:

1. Waist circumference and BMI be determined at every visit (19), using the National Health and Nutrition Examination Survey method, which is easy to perform, valid, and reproducible. Waist circumference is measured at the top of the iliac crest with the patient standing, using a nonfolded tape held parallel to the ground at the end of expiration. A waist circumference of at least 88 cm (35 inches) in Caucasian/African-American women or at least 80 cm (31.5 inches) in Hispanic, Native American, Asian (East and South), and European women is the easiest way to establish the presence of abdominal obesity (19).

2. A complete lipid profile (total cholesterol, LDL-C, non-HDL-C, HDL-C, and triglycerides) be determined. Based upon AHA guidelines (Table 2) (89), if the fasting serum lipid profile is normal, we suggest that it be reassessed every 2 yr or sooner if weight gain occurs. The primary target goal is LDL-C, with non-HDL-C estimating numbers of circulating small and large LDL particles as the secondary target for lifestyle and medical therapy (19, 89). We recommend that in women with PCOS without additional CVD risk factors, LDL-C levels should be less than 130 mg/dl (3.37 mmol/liter). Those with MBS or T2DM/overt vascular/renal disease should have serum LDL-C levels less than 70–100 mg/dl (1.81–2.59 mmol/liter) or 70 mg/dl (1.81 mmol/liter), respectively (89). Optimal (target) serum non-HDL-C levels should be 30 mg/dl (0.77 mmol/liter) higher than the designated LDL-C goal (Table 2); serum triglyceride levels, as an independent CVD risk factor in women, should be less than 150 mg/dl (89).

Routine use of LDL subfractions appears premature (91) because it is unclear whether there is added benefit to traditional risk factor assessment. Routine apolipoprotein B testing is not recommended until it becomes universally standardized, although apolipoprotein B levels may be more accurate than non-HDL-C as a CVD risk predictor (92).

3. A 2-h post 75-g oral glucose challenge be performed in PCOS women with a BMI greater than 30 kg/m<sup>2</sup>, or alternatively in lean PCOS women with advanced age (>40 yr), personal history of gestational diabetes, or family history of T2DM (44, 93). This outpatient test appears to be the best screening tool to detect IGT or T2DM in women with PCOS, who often have a normal fasting glucose (44). We *suggest* that patients with normal glucose tolerance be re-screened every 2 yr or sooner if additional risk factors are identified. Those with IGT should be screened annually for developing T2DM (93), acknowledging efficacy of treating IGT, but not necessarily impaired fasting glucose, to prevent T2DM (93).

Hemoglobin A1c above 6.5% has been proposed as the defining criterion for diabetes (94). We endorse this criterion for risk assessment, but further studies will be needed to determine whether this criterion is useful in implementing lifestyle interventions and medical management for CVD prevention.

4. That BP be routinely checked at each visit. Ideal BP is 120 mm Hg systolic and 80 mm Hg diastolic or lower, and prehypertension should be detected and treated (95). BP control has the largest benefit for reducing CVD.

**TABLE 2.** PCOS risk categories and lipid target values<sup>a</sup>

	Risk	LDL target values, mg/dl (mmol/liter) <sup>b</sup>	Non-HDL target values, mg/dl (mmol/liter) <sup>b</sup>
PCOS	At optimal risk	≤130 (3.37)	≤160 (4.14)
PCOS with obesity, hypertension, dyslipidemia, cigarette smoking, IGT, subclinical vascular disease	At risk	≤130 (3.37)	≤160 (4.14)
PCOS with MBS	High risk	≤100 (2.59)	≤130 (3.37)
PCOS with MBS and other risk factors, <sup>c</sup> or with T2DM, or in presence of overt vascular and/or renal disease		≤70 (1.81)	≤100 (2.59)

<sup>a</sup> Values are based on at least 12-h fasting lipid determinations. Predictive utility for CVD events based on nonfasting lipoprotein lipid values has not yet been clearly validated.

<sup>b</sup> To convert mg/dl to mmol/liter, divide by 39.

<sup>c</sup> Odds of CVD increase with number of MBS components and with other risk factors, including smoking, poor diet, physical inactivity, obesity, family history of premature CVD (<55 yr of age in male relative, <65 yr of age in female relative) and subclinical vascular disease.

In addition, we *suggest* that women with PCOS be assessed for depression, anxiety, and quality of life.

### Primary Prevention of CVD in PCOS

#### Lifestyle modification

The committee recommends lifestyle modification as first-line therapy for safety, public health benefit, and avoidance of risks and side effects of drug use. For overweight/obese women with PCOS, lifestyle modification, including diet, exercise, smoking cessation, and behavioral techniques (96), can be used to reduce CVD risk (97). It has been shown that short-term weight-loss intervention in PCOS women decreases abdominal fat (98, 99) and reduces androgenicity (98, 100) and IR (98, 99); it also improves dyslipidemia (99), depression, and quality of life (78), although long-term weight loss is unlikely (96). In two large intervention studies, almost 60% relative risk reduction in conversion to diabetes mellitus occurred in obese individuals (BMI, >30 kg/m<sup>2</sup>) with IGT randomized to intensive lifestyle modification to reduce body weight by 5–7% (101, 102); less dramatic improvement occurred in less obese individuals (BMI, 25–30 kg/m<sup>2</sup>) (93). Lifestyle modification is

recommended as first-line therapy for all women with PCOS and is particularly important for those individuals with serum LDL-C levels greater than 160 mg/dl and/or non-HDL-C levels of at least 190 mg/dl (89).

A hypocaloric, low saturated fat, increased mono- and polyunsaturated fat diet (500–1000 kcal/d reduction; <30% calories from fat, <10% calories from saturated fat; increased consumption of fiber, whole-grain breads, cereals, fruits, and vegetables) is recommended, along with at least 30 min of moderate-intensity physical activity daily (93, 96, 101, 103) to maintain weight. Together, both reduce BMI and improve IR and cardiopulmonary function in overweight PCOS women (104) and provide greater reductions in fat mass in PCOS women (105). Modifying dietary macronutrient composition does not offer benefit for weight loss over conventional dietary approaches alone (103).

We suggest that overweight/obese PCOS women should initially attempt 5–10% weight loss to reduce obesity-related CVD risk factors, with long-term goals of achieving and maintaining reduced weight of 10 to 20% and a waist circumference of less than 88–80 cm, depending upon ethnicity (19) (Table 3).

**TABLE 3.** Lifestyle strategies and effectiveness for LDL reduction

Dietary factor	Dietary change	% estimated LDL reduction
Reduced saturated fat	Reduce saturated fat to 7% of total energy	8–10
Reduced trans fat	Reduce trans fat to 1% of total energy	2
Reduced dietary cholesterol	Reduce dietary cholesterol to <200 mg/d	3–5
Added plant stanols/sterols	Add plant stanols (2 g/d)	6–10
Added dietary fiber	Add viscous fiber (5–10 g/d)	3–5
Reduced weight	Reduce body weight by 7–10%	5–8
Total improvement		25–35

Modified from Ref. 19.

An individualized exercise program assures optimal compliance and includes group or home exercise and walking (10,000 steps = 30 min daily exercise; 15,000 steps are usually needed for weight loss). Even without weight loss, sedentary women with PCOS undergoing moderate-intensity exercise experience improved IR and dyslipidemia (106). Screening for premature CVD is important before initiating exercise. Cardiac stress testing should be performed if cardiac symptoms exist. Exercise should begin slowly to avoid physical stress (107).

Successful lifestyle management requires self-esteem and motivation (108, 109). Validated tools for screening, treating, and monitoring depression, abnormal eating patterns, and reduced life quality may be necessary for improving psychological symptoms and lifestyle management.

## Medical therapy

### *Insulin sensitizers*

Data regarding the effects of metformin on primary prevention of CVD are not consistent (110–118). Metformin has a small effect on body weight (less than 2–3% of BMI) (110, 112, 117) and may improve atherogenic dyslipidemia, increasing HDL-C and decreasing triglycerides (112, 114). However, in some studies, no changes in HDL-C or triglycerides were observed (115, 116). Metformin does not improve LDL-C or non-HDL-C (112, 114, 116) and should not be used when these lipid parameters are elevated. Metformin decreases circulating C-reactive protein (111) and may improve subclinical atherosclerosis, reducing carotid IMT and improving endothelial function (113, 118). The addition of metformin to lifestyle modification may be considered in those women who have MBS or subclinical atherosclerotic CVD, although more studies are needed to confirm this benefit. Medical treatment is not recommended for women with PCOS who have isolated hypertriglyceridemia and/or decreased HDL-C but do not have MBS or for those who are not considered to be at risk or at high risk.

The Committee suggests the use of metformin only in women with PCOS who are already undergoing lifestyle treatment and do not have improvement in IGT and in those women with IGT who are of normal weight, where weight loss is not appropriate. Although combined metformin/lifestyle modification to prevent T2DM in PCOS has not been established prospectively, small studies show that almost 30% of reproductive-aged women with PCOS have IGT, of whom one half revert to normal glucose tolerance with metformin (119–121). Improved glucose tolerance also has been shown in nonobese women with PCOS with IGT receiving thiazolidinediones (122), although increased bone fracture risk and exacerbation of preexisting congestive heart failure limit thiazolidinedione

use for primary CVD prevention (19). Whether metformin should be used in PCOS to prevent conversion of normal glucose tolerance to IGT is debatable (46, 121).

### **Cholesterol-lowering drugs**

Cholesterol-lowering drug therapy should be reserved for those patients with PCOS who have increased serum LDL-C and/or non-HDL-C levels. Intensity of cholesterol-lowering therapy should be adjusted to absolute lifetime risk of CVD (19, 123). Adult Treatment Panel III guidelines recommend reserving cholesterol-lowering drugs for women with serum LDL-C levels greater than 160 mg/dl and/or non-HDL-C levels of at least 190 mg/dl, regardless of age or ethnicity, although these drugs can be administered if LDL-C levels remain above 130 mg/dl (with at least two risk factors) despite 3 months of lifestyle modification (19). Lowering LDL-C levels to less than 70–100 mg/dl is appropriate for high-risk patients with MBS, T2DM, or overt vascular/renal disease (Table 2) (19, 89). Serum lipid levels can be repeated 6 wk after initiating therapy.

Although several lipid-lowering drugs exist and may be used (19, 124), only statins have been adequately studied in women with PCOS and have been shown to effectively lower LDL-C levels (116, 125). Several studies have shown that, in women with PCOS, statins diminish IR and inflammation, lower serum total and free testosterone levels, and improve endothelial dysfunction (116, 125–127). However, their use in pregnancy is contraindicated, and contraception is required.

In selected patients with severe dyslipidemia that is not adequately corrected by lifestyle modification and statins, dual pharmacotherapy may be required. It has been shown that the addition of metformin does not improve lipid levels further (116). Statins combined with a fibrate may be necessary when hypertriglyceridemia and low HDL levels coexist. Fenofibrate is preferred because of fewer drug interactions and the decreased risk of myopathy (19, 128). Nicotinic acid produces a favorable lipoprotein effect but requires careful monitoring for worsening glycemic control (19). Omega-3 fatty acids (4 g daily, pharmacy grade) are Food and Drug Administration (FDA) approved for serum triglyceride levels greater than 500 mg/dl (89).

### **Antihypertensives**

Pharmacotherapy is indicated for BP of at least 140 mm Hg systolic or 90 mm Hg diastolic (19). Because milder forms of elevated BP (or prehypertension) increase CVD risk, reducing BP to 120/80 mm Hg is optimal for long-term CVD prevention (19). The committee recommends combining pharmacotherapy with lifestyle modification for persistent hypertension in PCOS women, recognizing that multiple drug therapy is often required. Although

some investigators favor angiotensin-converting enzyme inhibitors and angiotensin receptor blockers over diuretics and beta-blockers, use of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers, as with diuretics and beta-blockers, is contraindicated in pregnancy and requires contraception.

### Antiobesity drugs

Phenteramine, sibutramine, and orlistat are FDA-approved weight loss medications. Some studies have shown that sibutramine combined with a hypocaloric diet improves weight loss, IR, and hypertriglyceridemia, as well as reducing serum free testosterone levels, more than hypocaloric diet alone (129, 130), but this drug may increase diastolic BP and heart rate (131) and is not approved during pregnancy. Orlistat induces a small weight reduction but without changing glucose-insulin homeostasis or lipid patterns (132). Because in PCOS the clinical experience with these agents is limited (103) and significant side effects may occur, the Committee does not recommend the use of weight loss medications in PCOS.

### Bariatric surgery

Bariatric surgery may induce a significant weight loss (up to 60%) (133) and improve diabetes, hypertension, and dyslipidemia, reducing mortality from CVD and cancer when compared with lifestyle modification. Long-term weight loss has been shown to be a reduction of 14–25% (134, 135). In women with PCOS, bariatric surgery has been shown to be effective (136, 137). In 12 morbidly obese women with PCOS, an average weight loss of 41 kg in 1 yr postoperatively improved hyperandrogenism, IR, dyslipidemia, and hypertension and reversed the PCOS diagnosis (137).

Bariatric surgery may be an option for severely obese women with PCOS, in whom long-term diet-based strategies are seldom successful (103, 138, 139). Surgically induced weight loss, however, must be balanced against the risks of surgery, including a 0.1–1.1% mortality rate, bowel obstruction, infection, esophagitis, and nutritional abnormalities (133) and should be performed only after standard weight loss strategies have failed in PCOS women with a BMI greater than 40 kg/m<sup>2</sup> or greater than 35 kg/m<sup>2</sup> with a high-risk obesity-related condition (139).

### Disclaimer

These Guidelines are not inclusive of all proper approaches or methods or exclusive of others and do not guarantee outcome or establish standards of care. They do not dictate treatment, which depends upon independent judgment for each patient. The AE-PCOS Society makes

no warranty, expressed or implied, regarding the Guidelines and excludes any warranties of merchantability and fitness for particular use, and shall not be liable for damages from use of information contained herein.

### Acknowledgments

The authors thank Lisa Moran, Ph.D.; Michelle Meyer, MPH; Judy Rager, MPH; and members of the AE-PCOS Society Board for their assistance with the review and preparation of this manuscript.

Address all correspondence and requests for reprints to: Enrico Carmina, M.D., Androgen Excess and PCOS Society, Via delle Croci 47, 90139 Palermo, Italy. E-mail: info@ae-society.org.

Disclosure Summary: The authors have nothing to declare.

### References

1. Diamanti-Kandarakis E, Kouli CR, Bergiele AT, Filandra FA, Tsianateli TC, Spina GG, Zapanti ED, Bartzis MI 1999 A survey of the polycystic ovary syndrome in the Greek island of Lesbos: hormonal and metabolic profile. *J Clin Endocrinol Metab* 84:4006–4011
2. Asunción M, Calvo RM, San Millán JL, Sancho J, Avila S, Escobar-Morreale HF 2000 A prospective study of the prevalence of the polycystic ovary syndrome in unselected Caucasian women from Spain. *J Clin Endocrinol Metab* 85:2434–2438
3. Azziz R, Woods KS, Reyna R, Key TJ, Knochenhauer ES, Yildiz BO 2004 The prevalence and features of the polycystic ovary syndrome in an unselected population. *J Clin Endocrinol Metab* 89:2745–2749
4. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF 2006 Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline. *J Clin Endocrinol Metab* 91:4237–4245
5. Carmina E 2009 Cardiovascular risk and events in polycystic ovary syndrome. *Climacteric* 12 (Suppl 1):22–25
6. Conway GS, Agrawal R, Betteridge DJ, Jacobs HS 1992 Risk factors for coronary artery disease in lean and obese women with the polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 37:119–125
7. Talbott E, Clerici A, Berga SL, Kuller L, Guzick D, Detre K, Daniels T, Engberg RA 1998 Adverse lipid and coronary heart disease risk profiles in young women with polycystic ovary syndrome: results of a case-control study. *J Clin Epidemiol* 51:415–422
8. Azziz R, Carmina E, Dewailly D, Diamanti-Kandarakis E, Escobar-Morreale HF, Futterweit W, Janssen OE, Legro RS, Norman RJ, Taylor AE, Witchel SF 2009 The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete task force report. *Fertil Steril* 91:456–488
9. Birdsall MA, Farquhar CM, White HD 1997 Association between polycystic ovaries and extent of coronary artery disease in women having cardiac catheterization. *Ann Intern Med* 126:32–35
10. Guzick DS, Talbott EO, Sutton-Tyrrell K, Herzog HC, Kuller LH, Wolfson Jr SK 1996 Carotid atherosclerosis in women with polycystic ovary syndrome: initial results from a case-control study. *Am J Obstet Gynecol* 174:1224–1232
11. Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS 1998 Mortality of women with polycystic ovary syndrome at long-term follow-up. *J Clin Epidemiol* 51:581–586



12. Wild S, Pierpoint T, McKeigue P, Jacobs H 2000 Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. *Clin Endocrinol (Oxf)* 52: 595–600
13. Christian RC, Dumesic DA, Behrenbeck T, Oberg AL, Sheedy 2nd PF, Fitzpatrick LA 2003 Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 88:2562–2568
14. Shaw LJ, Bairey Merz CN, Azziz R, Stanczyk FZ, Sopko G, Braunstein GD, Kelsey SF, Kip KE, Cooper-Dehoff RM, Johnson BD, Vaccarino V, Reis SE, Bittner V, Hodgson TK, Rogers W, Pepine CJ 2008 Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health–National Heart, Lung, and Blood Institute sponsored Women's Ischemia Syndrome Evaluation. *J Clin Endocrinol Metab* 93: 1276–1284
15. The Rotterdam ESHRE/ASRM-sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). *Hum Reprod* 19:41–47
16. Zawadki JK, Dunaif A 1992 Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif A, Givens JR, Haseltine FP, Merriam GR, eds. *Polycystic ovary syndrome*. Boston: Blackwell Scientific Publications; 377–384
17. Broekmans FJ, Knauff EA, Valkenburg O, Laven JS, Eijkemans MJ, Fauser BC 2006 PCOS according to the Rotterdam consensus criteria: change in prevalence among WHO-II anovulation and association with metabolic factors. *BJOG* 113:1210–1217
18. Ounpuu S, Negassa A, Yusuf S 2001 INTER-HEART: A global study of risk factors for acute myocardial infarction. *Am Heart J* 141:711–721
19. Rosenzweig JL, Ferrannini E, Grundy SM, Haffner SM, Heine RJ, Horton ES, Kawamori R, Endocrine Society 2008 Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an Endocrine Society Clinical Practice Guideline. *J Clin Endocrinol Metab* 93:3671–3689
20. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist GE, Williams Jr JW, Zaza S; GRADE Working Group 2004 Grading quality of evidence and strength of recommendations. *BMJ* 328:1490–1497
21. Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH, Montori VM 2008 A case for clarity, consistency, and helpfulness: state-of-the-art clinical practice guidelines in endocrinology using the grading of recommendations, assessment, development, and evaluation system. *J Clin Endocrinol Metab* 93:666–673
22. Belosi C, Selvaggi L, Apa R, Guido M, Romualdi D, Fulghesu AM, Lanzone A 2006 Is the PCOS diagnosis solved by ESHRE/ASRM? *Hum Reprod* 21:3108–3115
23. Abbott DH, Tarantal AF, Dumesic DA 2009 Fetal, infant, adolescent and adult phenotypes of polycystic ovary syndrome in prenatally androgenized female rhesus monkeys. *Am J Primatol* 71:776–784
24. Carmina E, Chu MC, Longo RA, Rini GB, Lobo RA 2005 Phenotypic variation in hyperandrogenic women influences the findings of abnormal metabolic and cardiovascular risk parameters. *J Clin Endocrinol Metab* 90:2545–2549
25. Welt CK, Gudmundsson JA, Arason G, Adams J, Palsdottir H, Gudlaugsdottir G, Ingadottir G, Crowley WF 2006 Characterizing discrete subsets of polycystic ovary syndrome as defined by the Rotterdam criteria: the impact of weight on phenotype and metabolic features. *J Clin Endocrinol Metab* 91:4842–4848
26. Moran L, Teede H 2009 Metabolic features of the reproductive phenotypes of polycystic ovary syndrome. *Hum Reprod Update* 15:477–488
27. Carmina E, Bucchieri S, Mansueto P, Rini G, Ferin M, Lobo RA 2009 Circulating levels of adipose products and differences in fat distribution in the ovulatory and anovulatory phenotypes of polycystic ovary syndrome. *Fertil Steril* 91(Suppl 4):1332–1335
28. Dewailly D, Catteau-Jonard S, Reyss AC, Leroy M, Pigny P 2006 Oligoanovulation with polycystic ovaries but not overt hyperandrogenism. *J Clin Endocrinol Metab* 91:3922–3927
29. Rizzo M, Berneis K, Hersberger M, Pepe I, Di Fede G, Rini GB, Spinass G, Carmina E 2009 Milder forms of atherogenic dyslipidemia in ovulatory versus anovulatory polycystic ovary syndrome phenotype. *Hum Reprod* 24:2286–2292
30. Barber TM, Wass JA, McCarthy MI, Franks S 2007 Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 66:513–517
31. Norman RJ, Hague WM, Masters SC, Wang XJ 1995 Subjects with polycystic ovaries without hyperandrogenaemia exhibit similar disturbances in insulin and lipid profiles as those with polycystic ovary syndrome. *Hum Reprod* 10:2258–2261
32. Cibula D, Cífková R, Fanta M, Poledne R, Zivny J, Skibová J 2000 Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of the polycystic ovary syndrome. *Hum Reprod* 15:785–789
33. Legro RS, Kuneselman AR, Dunaif A 2001 Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. *Am J Med* 111:607–613
34. Talbott EO, Zborowski JV, Rager JR, Boudreaux MY, Edmundowicz DA, Guzick DS 2004 Evidence for an association between metabolic cardiovascular syndrome and coronary and aortic calcification among women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 89:5454–5461
35. Macut D, Damjanovic S, Panidis D, Spanos N, Glisic B, Petakov M, Rousso D, Kourtis A, Bjekic J, Milic N 2006 Oxidised low-density lipoprotein concentration—early marker of an altered lipid metabolism in young women with PCOS. *Eur J Endocrinol* 155:131–136
36. Carmina E, Lobo RA 2004 Use of fasting blood to assess the prevalence of insulin resistance in women with polycystic ovary syndrome. *Fertil Steril* 82:661–665
37. DeUgarte CM, Bartolucci AA, Azziz R 2005 Prevalence of insulin resistance in the polycystic ovary syndrome using the homeostasis model assessment. *Fertil Steril* 83:1454–1460
38. Dunaif A, Segal KR, Futterweit W, Dobrjansky A 1989 Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. *Diabetes* 38:1165–1174
39. Corbould A 2008 Insulin resistance in skeletal muscle and adipose tissue in polycystic ovary syndrome: are the molecular mechanisms distinct from type II diabetes? *Panminerva Med* 50:279–294
40. Tominaga M, Eguchi H, Manaka H, Igarashi K, Kato T, Sekikawa A 1999 Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose. The Funagata Diabetes Study. *Diabetes Care* 22:920–924
41. Ford ES 2004 The metabolic syndrome and mortality from cardiovascular disease and all-causes: findings from the National Health and Nutrition Examination Survey II Mortality Study. *Atherosclerosis* 173:309–314
42. Isoaia B, Almgren P, Tuomi T, Forsén B, Lahti K, Nissén M, Taskiran MR, Groop L 2001 Cardiovascular morbidity and mortality associated with the metabolic syndrome. *Diabetes Care* 24: 683–689
43. Ehrmann DA, Barnes RB, Rosenfield RL, Cavaghan MK, Imperial J 1999 Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. *Diabetes Care* 22:141–146
44. Legro RS, Kuneselman AR, Dodson WC, Dunaif A 1999 Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women. *J Clin Endocrinol Metab* 84:165–169

45. Palmert MR, Gordon CM, Kartashov AI, Legro RS, Emans SJ, Dunaif A 2002 Screening for abnormal glucose tolerance in adolescents with polycystic ovary syndrome. *J Clin Endocrinol Metab* 87:1017–1023
46. Legro RS, Gnatuk CL, Kunesman AR, Dunaif A 2005 Changes in glucose tolerance over time in women with polycystic ovary syndrome: a controlled study. *J Clin Endocrinol Metab* 90:3236–3242
47. Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ 2001 Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. *Hum Reprod* 16:1995–1998
48. Boudreaux MY, Talbott EO, Kip KE, Brooks MM, Witchel SF 2006 Risk of T2DM and impaired fasting glucose among PCOS subjects: results of an 8-year follow-up. *Curr Diab Rep* 6:77–83
49. Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB 1985 Lipoprotein lipid concentration and cardiovascular risk in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 61:946–951
50. Berneis K, Rizzo M, Lazzarini V, Lazzaroni V, Fruzzetti F, Carmina E 2007 Atherogenic lipoprotein phenotype and low-density lipoproteins size and subclasses in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 92:186–189
51. Essah PA, Nestler JE, Carmina E 2008 Differences in dyslipidemia between American and Italian women with polycystic ovary syndrome. *J Endocrinol Invest* 31:35–41
52. Valkenburg O, Steegers-Theunissen RP, Smedts HP, Dallinga-Thie GM, Fauser BC, Westerveld EH, Laven JS 2008 A more atherogenic serum lipoprotein profile is present in women with polycystic ovary syndrome: a case-control study. *J Clin Endocrinol Metab* 93:470–476
53. Austin MA, King MC, Vranizan KM, Krauss RM 1990 Atherogenic lipoprotein phenotype. A proposed genetic marker for coronary heart disease risk. *Circulation* 82:495–506
54. Rizzo M, Berneis K 2005 Lipid triad or atherogenic lipoprotein phenotype: a role in cardiovascular prevention? *J Atheroscler Thromb* 12:237–239
55. Brunzell JD, Ayyobi AF 2003 Dyslipidemia in the metabolic syndrome and type 2 diabetes mellitus. *Am J Med* 115(Suppl 8A):24S–28S
56. Dunaif A 1997 Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis. *Endocr Rev* 18:774–800
57. Wild RA 2002 Long-term health consequences of PCOS. *Hum Reprod Update* 8:231–241
58. Berneis K, Rizzo M, Hersberger M, Rini GB, Di Fede G, Pepe I, Spinass GA, Carmina E 2009 Atherogenic forms of dyslipidaemia in women with polycystic ovary syndrome. *Int J Clin Pract* 63:56–62
59. Mudali S, Dobs AS, Ding J, Cauley JA, Szklo M, Golden SH 2005 Endogenous postmenopausal hormones and serum lipids: the atherosclerosis risk in communities studies. *J Clin Endocrinol Metab* 90:1202–1209
60. Scanu AM 1992 Lipoprotein(a). A genetic risk factor for premature coronary heart disease. *JAMA* 267:3326–3329
61. Kirchengast S, Huber J 2001 Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. *Hum Reprod* 16:1255–1260
62. Yildirim B, Sabir N, Kaleli B 2003 Relation of intra-abdominal fat distribution to metabolic disorders in nonobese patients with polycystic ovary syndrome. *Fertil Steril* 79:1358–1364
63. Good C, Tulchinsky M, Mauger D, Demers LM, Legro RS 1999 Bone mineral density and body composition in lean women with polycystic ovary syndrome. *Fertil Steril* 72:21–25
64. Carmina E, Bucchieri S, Esposito A, Del Puente A, Mansueto P, Di Fede G, Rini GB 2007 Abdominal fat quantity and distribution in women with Polycystic Ovary Syndrome and the extent of its relation to insulin resistance. *J Clin Endocrinol Metab* 92:2500–2505
65. Folsom AR, Kaye SA, Sellers TA, Hong CP, Cerhan JR, Potter JD, Prineas RJ 1993 Body fat distribution and 5-year risk of death in older women. *JAMA* 269:483–487
66. Ehrmann DA, Liljenquist DR, Kasza K, Azziz R, Legro RS, Ghazzi MN 2006 Prevalence and predictors of metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 91:48–53
67. Apridonidze T, Essah PA, Iuorno MJ, Nestler JE 2005 Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 90:1929–1935
68. Dokras A, Bochner M, Hollinrake E, Markham S, Vanvoorhis B, Jagasia DH 2005 Screening women with polycystic ovary syndrome for metabolic syndrome. *Obstet Gynecol* 106:131–137
69. Carmina E, Napoli N, Longo RA, Rini GB, Lobo RA 2006 Metabolic syndrome in polycystic ovary syndrome (PCOS): lower prevalence in southern Italy than in the USA and the influence of criteria for the diagnosis of PCOS. *Eur J Endocrinol* 154:141–145
70. Alvarez-Blasco F, Botella-Carretero JI, San Millán JL, Escobar-Morreale HF 2006 Prevalence and characteristics of the polycystic ovary syndrome in overweight and obese women. *Arch Intern Med* 166:2081–2086
71. Taponen S, Martikainen H, Järvelin MR, Sovio U, Laitinen J, Pouta A, Hartikainen AL, McCarthy MI, Franks S, Paldanius M, Ruokonen A, Northern Finland Birth Cohort 2004 Metabolic cardiovascular disease risk factors in women with self-reported symptoms of oligomenorrhea and/or hirsutism: Northern Finland Birth Cohort 1966 Study. *J Clin Endocrinol Metab* 89:2114–2118
72. Cascella T, Palomba S, De Sio I, Manguso F, Giallauria F, De Simone B, Tafuri D, Lombardi G, Colao A, Orio F 2008 Visceral fat is associated with cardiovascular risk in women with polycystic ovary syndrome. *Hum Reprod* 23:153–159
73. Diamanti-Kandarakis E, Spina G, Kouli C, Migdalis I 2001 Increased endothelin-1 levels in women with polycystic ovary syndrome and the beneficial effect of metformin therapy. *J Clin Endocrinol Metab* 86:4666–4673
74. Jones GL, Hall JM, Balen AH, Ledger WL 2008 Health-related quality of life measurement in women with polycystic ovary syndrome: a systematic review. *Hum Reprod Update* 14:15–25
75. Bishop SC, Basch S, Futterweit W 2009 Polycystic ovary syndrome, depression and affective disorders. *Endocr Pract* 15:475–482
76. Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A 2007 Increased risk of depressive disorders in women with polycystic ovary syndrome. *Fertil Steril* 87:1369–1376
77. Jedel E, Waern M, Gustafson D, Landén M, Eriksson E, Holm G, Nilsson L, Lind AK, Janson PO, Stener-Victorin E 2010 Anxiety and depression symptoms in women with polycystic ovary syndrome compared with controls matched for body mass index. *Hum Reprod* 25:450–456
78. Thomson RL, Buckley JD, Lim SS, Noakes M, Clifton PM, Norman RJ, Brinkworth GD 11 December 2009 Lifestyle management improves quality of life and depression in overweight and obese women with polycystic ovary syndrome. *Fertil Steril* DOI: 10.1016/j.fertnstert.2009.11.001
79. Benson S, Arck PC, Tan S, Hahn S, Mann K, Rifaie N, Janssen OE, Schedlowski M, Elsenbruch S 2009 Disturbed stress responses in women with polycystic ovary syndrome. *Psychoneuroendocrinology* 34:727–735
80. Sverrisdóttir YB, Mogren T, Kataoka J, Janson PO, Stener-Victorin E 2008 Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? *Am J Physiol Endocrinol Metab* 294:E576–E581
81. Wild RA, Grubb B, Hartz A, Van Nort JJ, Bachman W, Bartholomew M 1990 Clinical signs of androgen excess as risk factors for coronary artery disease. *Fertil Steril* 54:255–259
82. Talbott EO, Guzick DS, Sutton-Tyrrell K, McHugh-Pemu KP, Zborowski JV, Remsberg KE, Kuller LH 2000 Evidence for association between polycystic ovary syndrome and premature carotid atherosclerosis in middle-aged women. *Arterioscler Thromb Vasc Biol* 20:2414–2421

83. Carmina E, Orio F, Palomba S, Longo RA, Cascella T, Colao A, Lombardi G, Rini GB, Lobo RA 2006 Endothelial dysfunction in PCOS: role of obesity and adipose hormones. *Am J Med* 119:356.e1–356.e6
84. Luque-Ramírez M, Mendieta-Azcona C, Alvarez-Blasco F, Escobar-Morreale HF 2007 Androgen excess is associated with the increased carotid intima-media thickness observed in young women with polycystic ovary syndrome. *Hum Reprod* 22:3197–3203
85. Elting MW, Korsen TJ, Bezemer PD, Schoemaker J 2001 Prevalence of diabetes mellitus, hypertension and cardiac complaints in a follow-up study of a Dutch PCOS population. *Hum Reprod* 16:556–560
86. Solomon CG, Hu FB, Dunaif A, Rich-Edwards JE, Stampfer MJ, Willett WC, Speizer FE, Manson JE 2002 Menstrual cycle irregularity and risk for future cardiovascular disease. *J Clin Endocrinol Metab* 87:2013–2017
87. Krentz AJ, von Mühlen D, Barrett-Connor E 2007 Searching for polycystic ovary syndrome in postmenopausal women: evidence of a dose-effect association with prevalent cardiovascular disease. *Menopause* 14:284–292
88. Azevedo GD, Duarte JM, Souza MO, Costa-E-Silva TD, Soares EM, Maranhão TM 2006 Menstrual cycle irregularity as a marker of cardiovascular risk factors at postmenopausal years. *Arq Bras Endocrinol Metabol* 50:876–883
89. Mosca L 2007 Guidelines for prevention of cardiovascular disease in women: a summary of recommendations. *Prev Cardiol* 10(Suppl 4):19–25
90. Sir-Petermann T, Codner E, Pérez V, Echiburú B, Maliqueo M, Ladrón de Guevara A, Preisler J, Crisosto N, Sánchez F, Cassorla F, Bhasin S 2009 Metabolic and reproductive features before and during puberty in daughters of women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 94:1923–1930
91. Ip S, Lichtenstein AH, Chung M, Lau J, Balk EM 2009 Systematic review: association of low-density lipoprotein subfractions with cardiovascular outcomes. *Ann Intern Med* 150:474–484
92. Contois JH, McConnell JP, Sethi AA, Csako G, Devaraj S, Hoefner DM, Warnick GR 2009 Apolipoprotein B and cardiovascular disease risk: position statement from the AACC Lipoproteins and Vascular Diseases Division Working Group on Best Practices. *Clin Chem* 55:407–419
93. Salley KE, Wickham EP, Cheang KI, Essah PA, Karjane NW, Nestler JE 2007 Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess Society. *J Clin Endocrinol Metab* 92:4546–4556
94. Lorenzo C, Haffner SM 2010 Performance characteristics of the new definition of diabetes: the insulin resistance atherosclerosis study. *Diabetes Care* 33:335–337
95. Cushman WC 2007 JNC-7 guidelines: are they still relevant? *Curr Hypertens Rep* 9:380–386
96. Norman RJ, Davies MJ, Lord J, Moran LJ 2002 The role of lifestyle modification in polycystic ovary syndrome. *Trends Endocrinol Metab* 13:251–257
97. De Backer G, Ambrosioni E, Borch-Johnsen K, Brotons C, Cifkova R, Dallongeville J, Ebrahim S, Faergeman O, Graham I, Mancia G, Manger Cats V, Orth-Gomér K, Perk J, Pyörälä K, Rodicio JL, Sans S, Sansoy V, Sechtem U, Silber S, Thomsen T, Wood D 2003 European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. *Eur Heart J* 24:1601–1610
98. Holte J, Bergh T, Berne C, Wide L, Lithell H 1995 Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 80:2586–2593
99. Andersen P, Seljeflot I, Abdelnoor M, Arnesen H, Dale PO, Løvik A, Birkeland K 1995 Increased insulin sensitivity and fibrinolytic capacity after dietary intervention in obese women with polycystic ovary syndrome. *Metab Clin Exp* 44:611–616
100. Hoeger K, Davidson K, Kochman L, Cherry T, Kopin L, Guzik DS 2008 The impact of metformin, oral contraceptives, and lifestyle modification on polycystic ovary syndrome in obese adolescent women in two randomized, placebo-controlled clinical trials. *J Clin Endocrinol Metab* 93:4299–4306
101. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, Nathan DM, Diabetes Prevention Program Research Group 2002 Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. *N Engl J Med* 346:393–403
102. Tuomilehto J, Lindström J, Eriksson JG, Valle TT, Hämäläinen H, Ilanne-Parikka P, Keinänen-Kiukkaanniemi S, Laakso M, Louheranta A, Rastas M, Salminen V, Uusitupa M 2001 Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 344:1343–1350
103. Moran LJ, Pasquali R, Teede HJ, Hoeger KM, Norman RJ 2009 Treatment of obesity in polycystic ovary syndrome: a position statement of the Androgen Excess and Polycystic Ovary Syndrome Society. *Fertil Steril* 92:1966–1982
104. Vigorito C, Giallauria F, Palomba S, Cascella T, Manguso F, Lucci R, De Lorenzo A, Tafuri D, Lombardi G, Colao A, Orio F 2007 Beneficial effects of a three-month structured exercise training program on cardiopulmonary functional capacity in young women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 92:1379–1384
105. Bruner B, Chad K, Chizen D 2006 Effects of exercise and nutritional counseling in women with polycystic ovary syndrome. *Appl Physiol Nutr Metab* 31:384–391
106. Brown AJ, Setji TL, Sanders LL, Lowry KP, Otvos JD, Kraus WE, Svetkey PL 2009 Effects of exercise on lipoprotein particles in women with polycystic ovary syndrome. *Med Sci Sports Exerc* 41:497–504
107. Redberg RF, Benjamin EJ, Bittner V, Braun LT, Goff Jr DC, Havas S, Labarthe DR, Limacher MC, Lloyd-Jones DM, Mora S, Pearson TA, Radford MJ, Smetana GW, Spertus JA, Swegler EW 2009 ACCF/AHA 2009 performance measures for primary prevention of cardiovascular disease in adults: a report of the American College of Cardiology Foundation/American Heart Association task force on performance measures. *Circulation* 120:1296–1336
108. Teixeira PJ, Going SB, Houtkooper LB, Cussler EC, Metcalfe LL, Blew RM, Sardinha LB, Lohman TG 2004 Pretreatment predictors of attrition and successful weight management in women. *Int J Obes Relat Metab Disord* 28:1124–1133
109. Linde JA, Rothman AJ, Baldwin AS, Jeffery RW 2006 The impact of self-efficacy on behavior change and weight change among overweight participants in a weight loss trial. *Health Psychol* 25:282–291
110. Moghetti P, Castello R, Negri C, Tosi F, Perrone F, Caputo M, Zanolin E, Muggeo M 2000 Metformin effects on clinical features, endocrine and metabolic profiles, and insulin sensitivity in polycystic ovary syndrome: a randomized, double-blind, placebo-controlled 6-month trial, followed by open, long-term clinical evaluation. *J Clin Endocrinol Metab* 85:139–146
111. Morin-Papunen L, Rautio K, Ruokonen A, Hedberg P, Puukka M, Tapanainen JS 2003 Metformin reduces serum C-reactive protein levels in women with polycystic ovary syndrome. *J Clin Endocrinol Metab* 88:4649–4654
112. Rautio K, Tapanainen JS, Ruokonen A, Morin-Papunen LC 2005 Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome. *Eur J Endocrinol* 152:269–275
113. Diamanti-Kandaraki E, Alexandraki K, Protogerou A, Piperi C, Papamichael C, Aessopos A, Lekakis J, Mavrikakis M 2005 Metformin administration improves endothelial function in women with polycystic ovary syndrome. *Eur J Endocrinol* 152:749–756
114. Trolle B, Flyvbjerg A, Kesmodel U, Lauszus FF 2007 Efficacy of metformin in obese and non-obese women with polycystic ovary



- syndrome: a randomized, double-blinded, placebo-controlled cross-over trial. *Hum Reprod* 22:2967–2973
115. **Luque-Ramírez M, Alvarez-Blasco F, Botella-Carretero JI, Martínez-Bermejo E, Lasunción MA, Escobar-Morreale HF** 2007 Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome. *J Clin Endocrinol Metab* 92:2453–2461
  116. **Banaszewska B, Pawelczyk L, Spaczynski RZ, Duleba AJ** 2009 Comparison of simvastatin and metformin in treatment of polycystic ovary syndrome: prospective randomized trial. *J Clin Endocrinol Metab* 94:4938–4945
  117. **Nieuwenhuis-Ruifrok AE, Kuchenbecker WK, Hoek A, Middleton P, Norman RJ** 2009 Insulin sensitizing drugs for weight loss in women of reproductive age who are overweight or obese: systematic review and meta-analysis. *Hum Reprod Update* 15:57–68
  118. **Agarwal N, Rice SP, Bolusani H, Luzio SD, Dunseath G, Ludgate M, Rees DA** 2010 Metformin reduces arterial stiffness and improves endothelial function in young women with polycystic ovary syndrome: a randomized, placebo-controlled, crossover trial. *J Clin Endocrinol Metab* 95:722–730
  119. **Unlühizarci K, Kelestimur F, Bayram F, Sahin Y, Tutus A** 1999 The effects of metformin on insulin resistance and ovarian steroidogenesis in women with polycystic ovary syndrome. *Clin Endocrinol (Oxf)* 51:231–236
  120. **Arslanian SA, Lewy V, Danadian K, Saad R** 2002 Metformin therapy in obese adolescents with polycystic ovary syndrome and impaired glucose tolerance: amelioration of exaggerated adrenal response to adrenocorticotropin with reduction of insulinemia/insulin resistance. *J Clin Endocrinol Metab* 87:1555–1559
  121. **Sharma ST, Wickham 3rd EP, Nestler JE** 2007 Changes in glucose tolerance with metformin treatment in polycystic ovary syndrome: a retrospective analysis. *Endocr Pract* 13:373–379
  122. **Dereli D, Dereli T, Bayraktar F, Ozgen AG, Yilmaz C** 2005 Endocrine and metabolic effects of rosiglitazone in non-obese women with polycystic ovary disease. *Endocr J* 52:299–308
  123. **Brugts JJ, Yetgin T, Hoeks SE, Gotto AM, Shepherd J, Westendorp RG, de Craen AJ, Knopp RH, Nakamura H, Ridker P, van Domburg R, Deckers JW** 2009 The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. *BMJ* 338:b2376–2383
  124. **Rizzo M, Berneis K, Carmina E, Rini GB** 2008 How should we manage atherogenic dyslipidemia in women with polycystic ovary syndrome? *Am J Obstet Gynecol* 198:28.e1–28.e5
  125. **Sathyapalan T, Kilpatrick ES, Coady AM, Atkin SL** 2009 The effect of atorvastatin in patients with polycystic ovary syndrome: a randomized double-blind placebo-controlled study. *J Clin Endocrinol Metab* 94:103–108
  126. **Duleba AJ, Banaszewska B, Spaczynski RZ, Pawelczyk L** 2006 Simvastatin improves biochemical parameters in women with polycystic ovary syndrome: results of a prospective, randomized trial. *Fertil Steril* 85:996–1001
  127. **Banaszewska B, Pawelczyk L, Spaczynski RZ, Dziura J, Duleba AJ** 2007 Effects of simvastatin and oral contraceptive agent on polycystic ovary syndrome: prospective, randomized, crossover trial. *J Clin Endocrinol Metab* 92:456–461
  128. **Zambon A, Cusi K** 2007 The role of fenofibrate in clinical practice. *Diab Vasc Dis Res* 4(Suppl 3):S15–S20
  129. **Lindholm A, Bixo M, Björn I, Wölnner-Hanssen P, Eliasson M, Larsson A, Johnson O, Poromaa IS** 2008 Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial. *Fertil Steril* 89:1221–1228
  130. **Florakis D, Diamanti-Kandarakis E, Katsikis I, Nassis GP, Karkanaki A, Georgopoulos N, Panidis D** 2008 Effect of hypocaloric diet plus sibutramine treatment on hormonal and metabolic features in overweight and obese women with polycystic ovary syndrome: a randomized, 24-week study. *Int J Obes (Lond)* 32:692–699
  131. **Jordan J, Scholze J, Matiba B, Wirth A, Hauner H, Sharma AM** 2005 Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. *Int J Obes* 29:509–516
  132. **Jayagopal V, Kilpatrick ES, Holding S, Jennings PE, Atkin SL** 2005 Orlistat is as beneficial as metformin in the treatment of polycystic ovarian syndrome. *J Clin Endocrinol Metab* 90:729–733
  133. **Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K** 2004 Bariatric surgery: a systematic review and meta-analysis. *JAMA* 292:1724–1737
  134. **Sjöström L, Lindroos AK, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren S, Larsson B, Narbro K, Sjöström CD, Sullivan M, Wedel H, Swedish Obese Subjects Study Scientific Group** 2004 Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. *N Engl J Med* 351:2683–2693
  135. **Sjöström L, Narbro K, Sjöström CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lönroth H, Näslund I, Olbers T, Stenlöf K, Torgerson J, Agren G, Carlsson LM, Swedish Obese Subjects Study** 2007 Effects of bariatric surgery on mortality in Swedish obese subjects. *N Engl J Med* 357:741–752
  136. **Eid GM, Cottam DR, Velcu LM, Mattar SG, Korytkowski MT, Gosman G, Hindi P, Schauer PR** 2005 Effective treatment of polycystic ovarian syndrome with Roux-en-Y gastric bypass. *Surg Obes Relat Dis* 1:77–80
  137. **Escobar-Morreale HF, Botella-Carretero JI, Alvarez-Blasco F, Sancho J, San Millán JL** 2005 The polycystic ovary syndrome associated with morbid obesity may resolve after weight loss induced by bariatric surgery. *J Clin Endocrinol Metab* 90:6364–6369
  138. **Yanovski SZ, Yanovski JA** 2002 Obesity. *N Engl J Med* 346:591–602
  139. 1992 Gastrointestinal surgery for severe obesity: National Institutes of Health Consensus Development Conference Statement. *Am J Clin Nutr* 55(Suppl 2):615S–619S